



January 11, 2016
Announcement no. 02

BioPorto enters distribution agreement with Siemens Healthcare

BioPorto has entered into a distribution agreement with Siemens Healthcare, under which BioPorto will deliver an NGAL test adapted for Siemens Healthcare's BN II and BN ProSpec Systems. The agreement is exclusive with regard to those instruments and has a worldwide scope. Siemens Healthcare's BN Systems are controlled systems that are designed for validated applications. Subsequent to completion of the adaptation of the NGAL test to those instruments, the agreement includes a period in which Siemens Healthcare and BioPorto will collaborate to bring the adapted test to market. Commercial sales will commence after completion of the adaptation. The agreement has significant strategic importance to the availability of NGAL tests and the awareness of NGAL as a diagnostic marker. BioPorto expects to see an economic effect of this agreement in the second half of 2016.

BioPorto's expectations for 2016 will be published in the annual report for 2015 and the expected economic effect of the agreement will be included herein.

For further information, please contact:

Peter Mørch Eriksen, CEO
Christina Thomsen, Investor Relations Manager
Telephone +45 4529 0000, e-mail investor@bioporto.com

The kidney biomarker NGAL

Every year about 13 million people are struck by acute kidney injury worldwide, of whom about 4 million die. Nevertheless, there has been no real progress in methods of diagnosing kidney injury over the last half century. Existing methods, such as serum creatinine determination, only signal kidney failure 24-72 hours after the injury has taken place. In contrast, NGAL rises to diagnostic levels within a few hours of kidney injury and thus enables the physician to make vital clinical decisions before the damage progresses to potentially fatal renal shutdown. In addition to helping the patient, cost-benefit analyses show that implementing NGAL testing will contribute to reducing hospital costs in the management of kidney injury and its consequences.

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ Copenhagen stock exchange.